UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

o

Rule 13d-1(b)

o

Rule 13d-1(c)

ý

Rule 13d-1(d)

CUSIP No. 45104P104

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Abbott Laboratories

36-0698440

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

o N/A

(b)

o N/A

3.

SEC Use Only

4.

Citizenship or Place of Organization
Illinois

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
1,646,535

6.

Shared Voting Power 
None

7.

Sole Dispositive Power 
1,646,535

8.

Shared Dispositive Power
None

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
1,646,535

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
N/A

11.

Percent of Class Represented by Amount in Row (9)
7.5%

12.

Type of Reporting Person (See Instructions)
CO

Item 1.

(a)

Name of Issuer
Icagen, Inc.

(b)

Address of Issuer’s Principal Executive Offices
4222 Emperor Boulevard, Suite 350

Durham, North Carolina 27703

Item 2.

(a)

Name of Person Filing
Abbott Laboratories

(b)

Address of Principal Business Office or, if none, Residence
100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(c)

Citizenship
Illinois

(d)

Title of Class of Securities
Common Stock, $0.001 par value

(e)

CUSIP Number
45104P104

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

o

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b)

o

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c)

o

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d)

o

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

(e)

o

An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)

o

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)

o

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

o

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

o

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

o

Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Not Applicable

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)

Amount beneficially owned:   

1,646,535 shares

(b)

Percent of class:   

7.5%

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote   

1,646,535 shares

(ii)

Shared power to vote or to direct the vote    

None

(iii)

Sole power to dispose or to direct the disposition of   

1,646,535 shares

(iv)

Shared power to dispose or to direct the disposition of   

None

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   o.

N/A

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

N/A

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

N/A

Item 8.

Identification and Classification of Members of the Group

N/A

Item 9.

Notice of Dissolution of Group

N/A

Item 10.

Certification

N/A

Date: February14, 2006

Abbott Laboratories

By:

/s/ Thomas C. Freyman

Name: Thomas C. Freyman

Title: Executive Vice President, Finance and

 Chief Financial Officer